Essa Pharma Inc. EPIX
Institutional shares held
31 Million
24.1K
calls
15.1K
puts
Total value of holdings
$54.3M
$42K
calls
$26K
puts
Market Cap
$75.8M
44,073,100
Shares Out.
Institutional ownership
70.38%
# of Institutions
47
We take great care to ensure that the data presented and summarized in this overview for ESSA Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EPIX
View all-
Bvf Inc San Francisco, CA8.75MShares$15 Million0.59% of portfolio
-
Tang Capital Management LLC San Diego, CA4.3MShares$7.4 Million0.58% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.22MShares$7.26 Million4.69% of portfolio
-
Morgan Stanley New York, NY4.2MShares$7.22 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.26MShares$3.89 Million0.28% of portfolio
-
Opaleye Management Inc. Boston, MA2.21MShares$3.8 Million0.78% of portfolio
-
Altium Capital Management LP New York, NY1.43MShares$2.46 Million0.85% of portfolio
-
Rtw Investments, LP New York, NY1.11MShares$1.91 Million0.03% of portfolio
-
Bank Of America Corp Charlotte, NC812KShares$1.4 Million0.0% of portfolio
-
Aldebaran Capital, LLC Indianapolis, IN398KShares$683,7390.68% of portfolio
Latest Institutional Activity in EPIX
Top Purchases
Top Sells
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Insider Transactions at EPIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Growth N V Biotech |
SELL
Open market or private sale
|
Direct |
7,879,583
-52.74%
|
$7,879,583
$1.53 P/Share
|
|
Oct 07
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-8.19%
|
$4,164
$6.03 P/Share
|
|
Sep 09
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-7.57%
|
$4,164
$6.0 P/Share
|
|
Sep 03
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,082
-18.51%
|
$12,492
$6.03 P/Share
|
|
May 06
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.81%
|
$4,164
$6.95 P/Share
|
|
Apr 24
2024
|
Richard M Glickman |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+7.98%
|
$15,000
$4.9 P/Share
|
|
Apr 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.49%
|
$4,858
$7.94 P/Share
|
|
Mar 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.21%
|
$5,552
$8.98 P/Share
|
|
Feb 06
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
72,782
-84.52%
|
$727,820
$10.29 P/Share
|
|
Feb 06
2024
|
Peter Virsik Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
72,782
+45.81%
|
$218,346
$3.23 P/Share
|
|
Feb 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,194
-4.28%
|
$10,746
$9.65 P/Share
|
|
Feb 05
2024
|
Peter Virsik Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+3.49%
|
$1,500
$3.23 P/Share
|
|
Jan 16
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,718
-10.91%
|
$17,180
$10.01 P/Share
|
|
Jan 16
2024
|
Peter Virsik Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,718
+9.84%
|
$5,154
$3.23 P/Share
|
|
Jan 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
699
-4.75%
|
$4,194
$6.11 P/Share
|
|
Dec 14
2023
|
David Ross Parkinson Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,223
+12.31%
|
$18,446
$2.3 P/Share
|
|
Nov 21
2023
|
Franklin M Berger |
BUY
Open market or private purchase
|
Direct |
23,259
+2.88%
|
$116,295
$5.73 P/Share
|
|
Nov 06
2023
|
Scott Requadt |
SELL
Other acquisition or disposition
|
Direct |
12,500
-29.41%
|
-
|
|
Nov 03
2023
|
Franklin M Berger |
BUY
Open market or private purchase
|
Direct |
16,471
+2.12%
|
$82,355
$5.99 P/Share
|
|
Nov 02
2023
|
Franklin M Berger |
BUY
Open market or private purchase
|
Direct |
60,000
+7.46%
|
$300,000
$5.35 P/Share
|
Last 12 Months Summary
Buy / Acquisition
3.75K
Shares
From
1
Insiders
| Exercise of conversion of derivative security | 3.75K shares |
|---|
Sell / Disposition
7.89M
Shares
From
2
Insiders
| Open market or private sale | 7.89M shares |
|---|